Quick Answer
Gain Therapeutics, Inc. reported Operating Income of -$18.71 million for fiscal year 2025.
Gain Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$18.71M | +8.1% |
| 2024 | -$20.35M | +8.5% |
| 2023 | -$22.25M | -25.2% |
| 2022 | -$17.78M | -28.6% |
| 2021 | -$13.83M | -297.4% |
| 2020 | -$3.48M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$4.79M | -7.3% | +6.0% |
| June 30, 2025 | -$5.09M | +37.8% | -16.5% |
| March 31, 2025 | -$4.37M | +0.2% | +2.0% |
| September 30, 2024 | -$4.46M | +8.7% | +45.5% |
| June 30, 2024 | -$8.18M | -5.8% | -86.9% |
| March 31, 2024 | -$4.38M | +16.3% | +10.4% |
| September 30, 2023 | -$4.89M | -2.8% | +36.8% |
| June 30, 2023 | -$7.73M | -49.4% | -47.8% |
- Gain Therapeutics, Inc. showed an increase of +8.1% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Gain Therapeutics, Inc.’s operating income has declined by 437.7% (from -$3.48 million to -$18.71 million).
- The most recent figure is from Gain Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: